IL6 and congenital rubella syndrome: In addition, pharmacologic agents such as tocilizumab, a monoclonal antibody against IL-6, have shown great promise in treating CAR-T related CRS, thereby providing both a potential treatment and endpoint for the clinical deterioration (35).